Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Luspatercept in Pediatric Participants With Beta-Thalassemia
NCT04143724Phase 2Recruiting
- Sponsor
- Celgene Corporation
- Start
- Nov 2019
- Primary completion
- Jan 2028
- Modality
- Fc-Fusion Proteins
- Countries
- 9
01
Overview
Phase 2, open-label trial of luspatercept in beta thalassemia (9 cohorts), sponsored by Celgene Corporation. Primary endpoints: Recommended Dose, Maximum Observed Plasma Concentration up to 1 year and 4 more. Started Nov 2019; status: recruiting.
02
Drugs
luspatercept
03
Conditions
beta thalassemia
Beyond the preview
Go deeper on NCT04143724.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04143724.